Open Nav

Please submit your session questions in advance at

Catalyst Biosciences

  • Nassim Usman, Catalyst Biosciences

Catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options.

We used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia.

  • Date:Tuesday, February 12
  • Time:1:15 PM - 1:30 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23498
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Progress Update
  • Company
  • Company HQ City:South San Francisco
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:CBIO
  • Exchange:Nasdaq
  • CEO/Top Company Official:Nassim Usman
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development:FVIIa - marzeptacog alfa (activated)
  • Development Phase of Primary Product:Phase II
Nassim Usman
Catalyst Biosciences